Following FDA approval of lifileucel for advanced melanoma in early 2024, U.S. centers have been learning how to best deliver this novel “living” drug. For #ASCODailyNews, @maxjulve.bsky.social & @drbetofmdphd.bsky.social discuss the real-world challenges facing clinicians: https://bit.ly/48nBPor
